181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1)

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Abemaciclib▼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Cancer Nursing Practice ◽

10.7748/cnp.2020.e1658 ◽

2020 ◽

Author(s):

Pauline Mcllroy

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3

European Journal of Cancer ◽

10.1016/j.ejca.2018.08.011 ◽

2018 ◽

Vol 104 ◽

pp. 21-31 ◽

Cited By ~ 17

Author(s):

Massimo Cristofanilli ◽

Angela DeMichele ◽

Carla Giorgetti ◽

Nicholas C. Turner ◽

Dennis J. Slamon ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer

Expert Review of Anticancer Therapy ◽

10.1080/14737140.2020.1834385 ◽

2020 ◽

pp. 1-12

Author(s):

Georges El Hachem ◽

Andrea Gombos ◽

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-09-01 ◽

2018 ◽

Cited By ~ 4

Author(s):

HS Rugo ◽

P Kabos ◽

MN Dickler ◽

WJ John ◽

I Smith ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 1B ◽

Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyr020 ◽

2011 ◽

Vol 41 (5) ◽

pp. 593-599 ◽

Cited By ~ 43

Author(s):

H. J. Chang ◽

S.-W. Han ◽

D.-Y. Oh ◽

S.-A. Im ◽

Y. K. Jeon ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Status ◽

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

10.1158/1538-7445.am2020-ct108 ◽

2020 ◽

Author(s):

Hope S. Rugo ◽

J. Thad Beck ◽

Guy Jerusalem ◽

Hans Wildiers ◽

Peter Kabos ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 1B ◽

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Advances in Therapy ◽

10.1007/s12325-020-01552-2 ◽

2020 ◽

Author(s):

Gayathri Nagaraj ◽

Cynthia X. Ma

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Literature Review ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial)

10.1158/1538-7445.sabcs19-ot2-04-07 ◽

2020 ◽

Author(s):

Jun Masuda ◽

Junji Tsurutani ◽

Norikazu Masuda ◽

Manabu Futamura ◽

Koji Matsumoto ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US

Current Medical Research and Opinion ◽

10.1185/03007995.2015.1130691 ◽

2016 ◽

Vol 32 (2) ◽

pp. 385-394 ◽

Cited By ~ 5

Author(s):

Nanxin Li ◽

Yanni Hao ◽

Andrew Kageleiry ◽

Miranda Peeples ◽

Anna Fang ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

The Us ◽

A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer

Advances in Therapy ◽

10.1007/s12325-011-0050-0 ◽

2011 ◽

Vol 28 (8) ◽

pp. 603-614 ◽

Cited By ~ 5

Author(s):

Zoe Kemp ◽

Alison Jones

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Human Epidermal Growth Factor ◽